eligibility_summary
Eligibility: adults (≥18) with histologically confirmed salivary gland carcinoma, tumor IHC for HER2/NTRK/AR/TROP‑2, ECOG 0–1, life expectancy >3 mo, measurable disease (RECIST 1.1), adequate organ function, negative pregnancy test/contraception, consent and compliance. Exclude: hypersensitivity, major surgery or live vaccine <4 wks, thrombosis <6 mo, major CV disease, uncontrolled systemic disease, active infection/TB, HIV, HBV/HCV, pregnancy/breastfeeding, other safety risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 biomarker-driven platform in recurrent/metastatic salivary gland carcinoma. Drugs/types/mechanisms: HER2: disitamab vedotin and trastuzumab deruxtecan (HER2 ADCs, MMAE or topo I payloads), trastuzumab/pertuzumab (HER2 mAbs), pyrotinib (irreversible pan‑HER TKI) ± taxane. NTRK: larotrectinib/entrectinib (TRK TKIs). AR: leuprolide/goserelin (GnRH agonists), bicalutamide/darolutamide (AR antagonists), abiraterone (CYP17A1 inhibitor) ± docetaxel. TROP‑2: sacituzumab govitecan/sacituzumab tirumotecan/ESG401 (TROP‑2 ADCs, topo I payloads). ACC‑TKI: apatinib/anlotinib (anti‑angiogenic multikinase TKIs). Nectin‑4: enfortumab vedotin (ADC, MMAE) ± PD‑1 ICI. Immunotherapy: ivonescimab (PD‑1/VEGF‑A bispecific), cadonilimab (PD‑1/CTLA‑4 bispecific), iparomlimab + tuvonralimab (PD‑1/PD‑L1 blockade) ± bevacizumab. HR+/PI3Kmut/HRD: CDK4/6 inhibitors + AI or fulvestrant (ER pathway), alpelisib + fulvestrant (PI3Kα/ER), PARP inhibitors (DNA repair). Chemo: nab‑paclitaxel + platinum ± apatinib + camrelizumab. Targets: HER2/ErbB, TRK, AR, TROP‑2, VEGF/angiogenesis, Nectin‑4, PD‑1/PD‑L1/CTLA‑4, ER/CDK4‑6, PI3Kα, PARP, microtubules, DNA crosslinks.